Agalsidase beta biosimilar

Drug Profile

Agalsidase beta biosimilar

Alternative Names: Fabagal; ISU-303

Latest Information Update: 24 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ISU Abxis
  • Class Galactosidases; Isoenzymes
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 07 May 2012 Phase-II clinical trials in Fabry's disease in South Korea (IV)
  • 13 Feb 2012 ISU Abxis plans a phase II trial for Fabry's disease in South Korea
  • 31 Jan 2012 Clinical trials in Fabry's disease in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top